Tumor Biomarkers and Precision Therapy: Epigenetic, Immune, and Proteomic Strategies
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 18
Special Issue Editors
Interests: solid tumors; proteins; gene editing; therapy resistance; metastasis; personalized medicine
Interests: label-free proteomics; mass spectrometry-based omics; cell proteome profiling; triple- negative breast cancer
Special Issue Information
Dear Colleagues,
Precision oncology increasingly relies on the systematic identification and integration of tumor biomarkers to address the molecular complexity of cancer. Epigenetic, immune, and proteomic strategies are among the most promising in providing critical insights into cancer biology and therapeutic strategies. Epigenetic biomarkers, including DNA methylation and histone modifications, act as reversible regulators of gene expression and offer unique opportunities for therapeutic modulation. In parallel, immune-related biomarkers, such as checkpoint ligand expression, but also tumor-infiltrating lymphocyte signatures and the cytokine landscape, capture the dynamic interplay between tumors and the immune system, revealing critical immunoregulatory pathways and targets. Complementing these dimensions, proteomics approaches offer a functional perspective by measuring protein abundance, post-translational modifications, and pathway expression patterns, thereby linking molecular alterations to cellular phenotypes. Taken together, these approaches open new avenues for mechanistic studies and targeted therapeutic interventions, as well as prediction of treatment responsiveness and resistance.
This Special Issue aims to highlight current advances in the discovery and application of epigenetic, immune, and proteomic approaches in the oncological field. We welcome submissions that explore the following:
- Novel biomarkers with discriminatory clinical or diagnostic value;
- Biomarker indicators of therapy response;
- Biomarkers implicated in drug repositioning;
- Novel therapy targets;
- Biosignatures related to treatment resistance.
We invite both original research articles, including in vitro, in vivo, and pre-clinical research, and review papers that summarize integrative perspectives on epigenetic, immune, and proteomic biomarkers in cancer.
We look forward to receiving your contributions.
Dr. Ximena Maria Muresan
Dr. Ioana Ecaterina Pralea
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumors
- biomarkers
- epigenetics
- immune targets
- proteomics
- mass-spectrometry based proteomics
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
